Exane Derivatives Takeda Pharmaceutical CO LTD Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
Shares
4 transactions
Others Institutions Holding TAK
# of Institutions
337Shares Held
73.8MCall Options Held
1.96MPut Options Held
165K-
Capital Research Global Investors Los Angeles, CA13.1MShares$178 Million0.04% of portfolio
-
Morgan Stanley New York, NY5.35MShares$72.6 Million0.01% of portfolio
-
Mondrian Investment Partners LTD London, X05.09MShares$69.1 Million1.21% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA4.64MShares$62.9 Million0.05% of portfolio
-
Goldman Sachs Group Inc New York, NY4.56MShares$61.8 Million0.01% of portfolio
About TAKEDA PHARMACEUTICAL CO LTD
- Ticker TAK
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 3,109,050,112
- Market Cap $42.2B
- Description
- Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived t...